AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu has received a positive cost-effectiveness assessment from the National Institute for Health and Care Excellence (NICE) for use in treating HER2-low advanced breast cancer. This decision comes after a previous rejection in 2024, marking a significant turnaround for the drug’s market access in England and Wales.
The NICE approval is pivotal, as it not only validates the clinical efficacy of Enhertu but also addresses the pressing need for effective therapies in a patient population that has limited options. The endorsement is expected to enhance patient access to this innovative treatment, potentially improving outcomes for those battling this challenging cancer subtype.
For pharmaceutical professionals, this development underscores the importance of navigating the regulatory landscape effectively, as well as the need for robust health economic data to support product value propositions. As the market evolves, stakeholders must remain vigilant in adapting to shifting guidelines and payer expectations.
Start your 7-day trial and see what the database can do →
